[April 23, 2014] |
|
Research and Markets: Global Varicella Zoster (HHV-3) Infections Therapeutics Pipeline Review 2014 - Analysis of 8 Companies & 11 Drug Profiles
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/6zwskn/varicella_zoster)
has announced the addition of the "Varicella
Zoster (HHV-3) Infections - Pipeline Review, H1 2014" report to
their offering.
This report provides comprehensive information on the therapeutic
development for Varicella Zoster (HHV-3) Infections, complete with
comparative analysis at various stages, therapeutics assessment by drug
target, mechanism of action (MoA), route of administration (RoA) and
molecule type, along with latest updates, and featured news and press
releases. It also reviews key players involved in the therapeutic
development for Varicella Zoster (HHV-3) Infections and special features
on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create
effective counter strategies to gain competitive advantage. It
strengthens R&D pipelines by identifying new targets and MOAs to produce
first-in-class and best-in-class products.
Scope
-
The report provides a snapshot of the global therapeutic landscape of
Varicella Zoster (HHV-3) Infections
-
The report reviews key pipeline products under drug profile section
which includes, product description, MoA and R&D brief, licensing and
collaboration details & other developmental activities
-
The report reviews key players involved in the therapeutics
development for Varicella Zoster (HHV-3) Infections and enlists all
their major and minor projects
-
The report summarizes all the dormant and discontinued pipeline
projects
-
A review of the Varicella Zoster (HHV-3) Infections products under
development by companies and universities/research institutes based on
information derived from company and industry-specific sources
-
Pipeline products coverage based on various stages of development
ranging from pre-registration till discovery and undisclosed stages
-
A detailed assessment of monotherapy and combination therapy pipeline
projects
-
Coverage of the Varicella Zoster (HHV-3) Infections pipeline on the
basis of target, MoA, route of administration and molecule type
-
Latest news and deals relating related to pipeline products
Companies Involved in Therapeutics Development
-
GlaxoSmithKline plc
-
Novavax, Inc.
-
SK Chemicals Co., Ltd.
-
Nutra Pharma Corporation
-
Green Cross Corporation
-
Beijing Tiantan Biological Products Co., Ltd.
-
Epiphany Biosciences, Inc.
-
Chongqing Zhifei Biological Products Co., Ltd.
Drug Profiles
-
GSK-208136
-
RPI-78M
-
valomaciclovir stearate
-
Varicella Vaccine
-
MG-1111
-
MMR + Varicella Vaccine
-
Varicella Vaccine
-
Varicella Zoster Virus Vaccine
-
Nonimmunosuppressive Cyclosporin Analog Molecule Program
-
Sattabacin
-
Second Generation Vaccine For VZV Infection
For more information visit http://www.researchandmarkets.com/research/6zwskn/varicella_zoster
[ Back To TMCnet.com's Homepage ]
|